- Home
- QGEN vs JAZZ Comparison
QGEN vs JAZZ Comparison
Compare QGEN & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QGEN | JAZZ |
|---|---|---|
| Founded | 1986 | 2003 |
| Country | Netherlands | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2B | 10.4B |
| IPO Year | 1998 | 2007 |
Fundamental Metrics
Financial Performance| Metric | QGEN | JAZZ |
|---|---|---|
| Price | $40.38 | $188.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | $51.30 | ★ $216.92 |
| AVG Volume (30 Days) | ★ 1.8M | 692.2K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 5.97% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,618,693,000.00 |
| Revenue This Year | $8.18 | $6.17 |
| Revenue Next Year | $5.66 | $7.66 |
| P/E Ratio | $24.01 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $38.13 | $95.49 |
| 52 Week High | $57.82 | $198.00 |
Technical Indicators
Market Signals| Indicator | QGEN | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 37.30 | 55.00 |
| Support Level | N/A | $159.78 |
| Resistance Level | $48.60 | $198.00 |
| Average True Range (ATR) | 0.89 | 4.31 |
| MACD | 0.22 | -0.09 |
| Stochastic Oscillator | 49.77 | 56.58 |
Price Performance
Historical ComparisonAbout QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.